Diabetes Self-Management Blog

A new study of an older, "real-world" population, published in the December 12 issue of The Journal of the American Medical Association (JAMA), has confirmed the findings of earlier research by linking Type 2 diabetes drug rosiglitazone (brand name Avandia) with increased heart risks. It has also uncovered a new risk associated with the drug—namely, an increased risk of dying that had not been observed before. Studies of rosiglitazone have made the news a lot lately (see our own recent coverage in "Avandia: New Warning and Findings").

In the new study, researchers examined medical records for more than 159,000 people, aged 66 and over, living in Ontario, Canada. The records covered a four-year period, during which all of the people studied took at least one oral diabetes drug.

When they were compared to people who were taking combinations of other diabetes drugs, people who took rosiglitazone on its own had a 60% increased risk of congestive heart failure, a 40% increased risk of heart attack, and a 29% increased risk of dying.

While other studies have associated rosiglitazone with an increased risk of heart attack and both thiazolidinedione drugs (rosiglitazone and pioglitazone [Actos]) with an increased risk of congestive heart failure, this was the first study to link rosiglitazone with an increase in mortality rates.

While the new study did not link pioglitazone with the same increase in risks, 50% fewer people examined in the study took pioglitazone than rosiglitazone, which the researchers say could have skewed the results. They have called for further studies of both drugs in the thiazolidinedione class.

It is important to note that observational studies such as this one do not provide the same quality of evidence as randomized, controlled clinical trials. While randomized clinical trials carefully select participants and randomly assign them to receive different treatments, this new study is a bit different in that it was observational and population-based, meaning that its participants made their own treatment choices in real life and data about them was examined after the fact. The new study also focused on an older group of people than most clinical trials usually feature.

Rosiglitazone’s manufacturer, GlaxoSmithKline, responded to the study by stating that the research “has significant limitations” and pointing out that its “conclusions are inconsistent with a more robust body of evidence from large, long-term, prospective, well-designed clinical studies.” However, Steven Nissen, M.D., lead author of the first analysis to raise questions about rosiglitazone’s heart safety (see “Type 2 Drug Linked to Increased Risk of Heart Attacks”), pointed out that the large size of this new study and the fact that it was conducted independently, without sponsorship from any drug company, count in its favor.

When it comes to using rosiglitazone, “in older people, the risks may outweigh the benefit,” said lead study author Lorraine L. Lipscombe, M.D., M.Sc. By providing a “snapshot” of the drug’s apparent effects in a real-world setting, this new study will likely help keep the debate going about whether rosiglitazone is a safe treatment option for various groups of people with Type 2 diabetes.

POST A COMMENT       
  

We are currently experiencing technical difficulties with our commenting system. Thank you for your patience as we work to resolve them.


Type 2 Diabetes
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
Discovering I Had Type 2 Diabetes (10/17/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)

Oral Medicines
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
Statins May Reduce Risk of Nerve Damage, Other Diabetes Complications (09/18/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)

Heart Health
Self-Manage Your Blood Pressure (09/02/14)
Pistachios Offer Protection for People With Diabetes (08/29/14)
Which Butter (or Spread) Is Better? (07/28/14)
High-Salt Diet Doubles Heart Risk in Type 2 Diabetes (07/25/14)

Diabetes Research
A Diabetes Cure in Mice (11/13/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)

Diabetes News
Mediterranean Diet May Benefit Kidneys (11/06/14)
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
FDA Approves Remote Glucose-Monitoring Technology (10/24/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.